Status:
UNKNOWN
Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
FONCER contre le cancer
Conditions:
Renal Cell Carcinoma
Renal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This is a multicenter, exploratory, prospective study to identify angiogenesis and immune-related biomarkers predictive of progression free survival in patients with metastatic or advanced renal cell ...
Detailed Description
Recently, the management of renal cell carcinoma has undergone major changes with the emergence of combined therapies associating tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI...
Eligibility Criteria
Inclusion
- Histologically proven advanced or metastatic renal carcinoma
- treated in first line with an ICI-ICI or ITK-ICI combination (following current recommendations at inclusion)
Exclusion
- Previous systemic treatment for renal cell carcinoma
- Other cancer developed in the last 5 years except local forms apparently healed as basal cell cancer.
- Contraindication for ICI-ICI or TKI-ICI combinations recommended on 1st line
- Refusal to participate in the study
- No affiliation to a social security regime (beneficiary or entitled)
- Vulnerable patients as defined by french law (Public Heath Code sections L1121 -5 to L1121-8) :
- Major patient subjected to legal protection (guardianship, curatorship, protection of justice)
- Pregnant or breastfeeding woman
Key Trial Info
Start Date :
May 5 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05285579
Start Date
May 5 2022
End Date
August 1 2025
Last Update
April 19 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital européen Georges-Pompidou AP-HP
Paris, France, 75015
2
Hôpital Cochin - AP-HP
Paris, France